AFM
BIOL

Anson Funds Management’s Biolase, Inc. BIOL Stock Holding History

Anson Funds Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-185,127
Closed -$208K – 224
2023
Q4 		$208K Buy
185,127
+133,846
+261% +$191K 0.03% 147
2023
Q3 		$95.4K Buy
+51,281
New +$271K 0.02% 125

Other funds holding BIOL

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
KWA
Kellett Wealth Advisors Cincinnati, Ohio $215M AUM 22.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Anson Funds Management's BIOL Position: Q1 2024 in Review

Anson Funds Management sold out of Biolase, Inc. (BIOL) in Q1 2024, closing a stake of 185,127 shares — an estimated $208K sold.

Anson Funds Management first reported a position in BIOL in Q3 2023 and held it in 2 quarters. The position peaked at $208K in Q4 2023. 18 funds tracked by Wall St. Rank hold BIOL as of Q1 2024.

  • Anson Funds Management reported no remaining Biolase, Inc. position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 185,127 Biolase, Inc. shares in Q1 2024, an estimated $208K.
  • Anson Funds Management first reported a position in Biolase, Inc. in Q3 2023 and held it in 2 quarters.
  • Anson Funds Management's Biolase, Inc. position peaked at $208K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.